150 related articles for article (PubMed ID: 21303614)
1. Proteomic analysis of serum opsonins impacting biodistribution and cellular association of porous silicon microparticles.
Serda RE; Blanco E; Mack A; Stafford SJ; Amra S; Li Q; van de Ven A; Tanaka T; Torchilin VP; Wiktorowicz JE; Ferrari M
Mol Imaging; 2011 Feb; 10(1):43-55. PubMed ID: 21303614
[TBL] [Abstract][Full Text] [Related]
2. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature.
Serda RE; Gu J; Bhavane RC; Liu X; Chiappini C; Decuzzi P; Ferrari M
Biomaterials; 2009 May; 30(13):2440-8. PubMed ID: 19215978
[TBL] [Abstract][Full Text] [Related]
3. Mitotic trafficking of silicon microparticles.
Serda RE; Ferrati S; Godin B; Tasciotti E; Liu X; Ferrari M
Nanoscale; 2009 Nov; 1(2):250-9. PubMed ID: 20644846
[TBL] [Abstract][Full Text] [Related]
4. Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles.
Keohane K; Brennan D; Galvin P; Griffin BT
Int J Pharm; 2014 Jun; 467(1-2):60-9. PubMed ID: 24680950
[TBL] [Abstract][Full Text] [Related]
5. In vitro assessment of biopolymer-modified porous silicon microparticles for wound healing applications.
Mori M; Almeida PV; Cola M; Anselmi G; Mäkilä E; Correia A; Salonen J; Hirvonen J; Caramella C; Santos HA
Eur J Pharm Biopharm; 2014 Nov; 88(3):635-42. PubMed ID: 25305585
[TBL] [Abstract][Full Text] [Related]
6. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity.
Huotari A; Xu W; Mönkäre J; Kovalainen M; Herzig KH; Lehto VP; Järvinen K
Int J Pharm; 2013 Sep; 454(1):67-73. PubMed ID: 23834832
[TBL] [Abstract][Full Text] [Related]
7. Multi-stage delivery nano-particle systems for therapeutic applications.
Serda RE; Godin B; Blanco E; Chiappini C; Ferrari M
Biochim Biophys Acta; 2011 Mar; 1810(3):317-29. PubMed ID: 20493927
[TBL] [Abstract][Full Text] [Related]
8. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles.
Limnell T; Riikonen J; Salonen J; Kaukonen AM; Laitinen L; Hirvonen J; Lehto VP
Int J Pharm; 2007 Oct; 343(1-2):141-7. PubMed ID: 17600644
[TBL] [Abstract][Full Text] [Related]
9. Biodegradation of inorganic drug delivery systems in subcutaneous conditions.
Kovalainen M; Kamakura R; Riikonen J; Finnilä M; Nissinen T; Rantanen J; Niemelä M; Perämäki P; Mäkinen M; Herzig KH; Lehto VP
Eur J Pharm Biopharm; 2018 Jan; 122():113-125. PubMed ID: 29056485
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers.
Shrestha N; Shahbazi MA; Araújo F; Zhang H; Mäkilä EM; Kauppila J; Sarmento B; Salonen JJ; Hirvonen JT; Santos HA
Biomaterials; 2014 Aug; 35(25):7172-9. PubMed ID: 24844163
[TBL] [Abstract][Full Text] [Related]
11. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles.
Bimbo LM; Mäkilä E; Raula J; Laaksonen T; Laaksonen P; Strommer K; Kauppinen EI; Salonen J; Linder MB; Hirvonen J; Santos HA
Biomaterials; 2011 Dec; 32(34):9089-99. PubMed ID: 21864895
[TBL] [Abstract][Full Text] [Related]
12. New times, new trends for ethionamide: In vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles.
Vale N; Mäkilä E; Salonen J; Gomes P; Hirvonen J; Santos HA
Eur J Pharm Biopharm; 2012 Jun; 81(2):314-23. PubMed ID: 22418076
[TBL] [Abstract][Full Text] [Related]
13. "Thunderstruck": Plasma-Polymer-Coated Porous Silicon Microparticles As a Controlled Drug Delivery System.
McInnes SJ; Michl TD; Delalat B; Al-Bataineh SA; Coad BR; Vasilev K; Griesser HJ; Voelcker NH
ACS Appl Mater Interfaces; 2016 Feb; 8(7):4467-76. PubMed ID: 26836366
[TBL] [Abstract][Full Text] [Related]
14. Cellular association and assembly of a multistage delivery system.
Serda RE; Mack A; Pulikkathara M; Zaske AM; Chiappini C; Fakhoury JR; Webb D; Godin B; Conyers JL; Liu XW; Bankson JA; Ferrari M
Small; 2010 Jun; 6(12):1329-40. PubMed ID: 20517877
[TBL] [Abstract][Full Text] [Related]
15. Encapsulation of antigen-loaded silica nanoparticles into microparticles for intradermal powder injection.
Deng Y; Mathaes R; Winter G; Engert J
Eur J Pharm Sci; 2014 Oct; 63():154-66. PubMed ID: 25042055
[TBL] [Abstract][Full Text] [Related]
16. Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics.
Wu EC; Andrew JS; Buyanin A; Kinsella JM; Sailor MJ
Chem Commun (Camb); 2011 May; 47(20):5699-701. PubMed ID: 21503283
[TBL] [Abstract][Full Text] [Related]
17. Tailored porous silicon microparticles: fabrication and properties.
Chiappini C; Tasciotti E; Fakhoury JR; Fine D; Pullan L; Wang YC; Fu L; Liu X; Ferrari M
Chemphyschem; 2010 Apr; 11(5):1029-35. PubMed ID: 20162656
[TBL] [Abstract][Full Text] [Related]
18. Capture, enrichment, and mass spectrometric detection of low-molecular-weight biomarkers with nanoporous silicon microparticles.
Tan J; Zhao WJ; Yu JK; Ma S; Sailor MJ; Wu JM
Adv Healthc Mater; 2012 Nov; 1(6):742-50. PubMed ID: 23184826
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size.
Santos HA; Riikonen J; Salonen J; Mäkilä E; Heikkilä T; Laaksonen T; Peltonen L; Lehto VP; Hirvonen J
Acta Biomater; 2010 Jul; 6(7):2721-31. PubMed ID: 20036766
[TBL] [Abstract][Full Text] [Related]
20. Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution.
Sarparanta M; Bimbo LM; Rytkönen J; Mäkilä E; Laaksonen TJ; Laaksonen P; Nyman M; Salonen J; Linder MB; Hirvonen J; Santos HA; Airaksinen AJ
Mol Pharm; 2012 Mar; 9(3):654-63. PubMed ID: 22277076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
